Aurobindo Pharma Acquires Lannett, FTC Mandates Divestitures

Aurobindo Pharma just got the green light from the U.S. Federal Trade Commission (FTC) to snap up Lannett Company for $250 million, but not without offloading four key generic drugs to keep competition fierce.

📌 What Happened?

Aurobindo Pharma USA secured U.S. Federal Trade Commission (FTC) approval for its $250 million acquisition of Pennsylvania-based generic drug maker Lannett Company. The deal, valued on a cash-free, debt-free basis including normalized working capital, is set to finalize before June 2026.

Lannett brings a specialized portfolio of complex, non-opioid controlled substances and a significant manufacturing facility in Seymour, Indiana. This facility can produce approximately 4 billion doses annually, aligning with U.S. policy goals for domestic pharmaceutical production and supply chain resilience.

To prevent potential anti-competitive practices and rising drug costs for American patients, the FTC mandated Aurobindo divest four specific generic pharmaceutical products. These products, including medications for organ transplant rejection prevention and dry mouth treatment, will be sold to Quagen Pharmaceuticals.

💰 Why It Matters

This acquisition significantly expands Aurobindo USA’s product range and integrates a crucial U.S.-based manufacturing site, boosting its domestic footprint in essential medicines. Swami S. Iyer, CEO of Aurobindo Pharma USA, views this as a strategic move promising immediate earnings accretion and long-term value creation.

The FTC’s intervention highlights regulatory scrutiny on pharmaceutical mergers, ensuring that consolidation doesn’t lead to reduced competition and higher prices for critical generic drugs. This protects consumers and maintains market fairness in the market for generic drugs.

For investors, the deal signals Aurobindo’s aggressive growth strategy in the U.S. market, particularly in specialized non-opioid controlled substances. The forced divestiture mitigates some regulatory risk, but also means a slight adjustment to the initial portfolio and revenue projections.

👀 What to Watch Next

Keep an eye on the finalization of the acquisition, expected before June 2026, and how Aurobindo integrates Lannett’s operations, especially its Indiana manufacturing facility. The focus will be on realizing the projected revenue growth and synergies.

Monitor the market impact of the divestiture of the four generic drugs to Quagen Pharmaceuticals. This will show how well the FTC’s mandate maintains competition and pricing stability in those specific product categories.

Watch for Aurobindo’s next moves in expanding its U.S. presence and product pipeline, particularly in complex generics, as the company leverages this acquisition for strategic positioning in a high-growth segment.